Data processing: measuring – calibrating – or testing – Measurement system in a specific environment – Biological or biochemical
Reexamination Certificate
2011-04-19
2011-04-19
Zhou, Shubo (Joe) (Department: 1631)
Data processing: measuring, calibrating, or testing
Measurement system in a specific environment
Biological or biochemical
C435S006120, C702S020000, C703S011000
Reexamination Certificate
active
07930104
ABSTRACT:
The present invention provides gene expression information useful for predicting whether a cancer patient is likely to have a beneficial response to treatment with chemotherapy, comprising measuring, in a biological sample comprising a breast tumor sample obtained from the patient, the expression levels of gene subsets to obtain a risk score associated with a likelihood of a beneficial response to chemotherapy, wherein the score comprises at least one of the following variables: (i) Recurrence Score, (ii) ESRI Group Score; (iii) Invasion Group Score; (iv) Proliferation Group Score; and (v) the expression level of the RNA transcript of at least one of MYBL2and SCUBE2, or the corresponding expression product. The invention further comprises a molecular assay-based algorithm to calculate the likelihood that the patient will have a beneficial response to chemotherapy based on the risk score.
REFERENCES:
patent: 4699877 (1987-10-01), Cline et al.
patent: 4968603 (1990-11-01), Slamon et al.
patent: 5015568 (1991-05-01), Tsujimoto et al.
patent: 5202429 (1993-04-01), Tsujimoto et al.
patent: 5459251 (1995-10-01), Tsujimoto et al.
patent: RE35491 (1997-04-01), Cline et al.
patent: 5670325 (1997-09-01), Lapidus et al.
patent: 5741650 (1998-04-01), Lapidus et al.
patent: 5830665 (1998-11-01), Shuber et al.
patent: 5830753 (1998-11-01), Coulie et al.
patent: 5858678 (1999-01-01), Chinnadurai
patent: 5861278 (1999-01-01), Wong et al.
patent: 5928870 (1999-07-01), Lapidus et al.
patent: 5952178 (1999-09-01), Lapidus et al.
patent: 5952179 (1999-09-01), Chinnadurai
patent: 5962312 (1999-10-01), Plowman et al.
patent: 5985553 (1999-11-01), King et al.
patent: 6020137 (2000-02-01), Lapidus et al.
patent: 6100029 (2000-08-01), Lapidus et al.
patent: 6143529 (2000-11-01), Lapidus et al.
patent: 6146828 (2000-11-01), Lapidus et al.
patent: 6171798 (2001-01-01), Levine et al.
patent: 6203993 (2001-03-01), Shuber et al.
patent: 6207401 (2001-03-01), Plowman et al.
patent: 6207452 (2001-03-01), Govindaswamy
patent: 6214558 (2001-04-01), Shuber et al.
patent: 6245523 (2001-06-01), Altieri
patent: 6248535 (2001-06-01), Danenberg et al.
patent: 6271002 (2001-08-01), Linsley et al.
patent: 6322986 (2001-11-01), Ross
patent: 6414134 (2002-07-01), Reed
patent: 6582919 (2003-06-01), Danenberg
patent: 6602670 (2003-08-01), Danenberg
patent: 6618679 (2003-09-01), Loehrlein et al.
patent: 6620606 (2003-09-01), Bandman et al.
patent: 6696558 (2004-02-01), Reed et al.
patent: 6716575 (2004-04-01), Plowman et al.
patent: 6750013 (2004-06-01), Gish et al.
patent: 6800737 (2004-10-01), Altieri
patent: 6943150 (2005-09-01), Altieri
patent: 2002/0004491 (2002-01-01), Xu et al.
patent: 2002/0009736 (2002-01-01), Wang
patent: 2002/0039764 (2002-04-01), Rosen
patent: 2002/0160395 (2002-10-01), Altieri et al.
patent: 2003/0073112 (2003-04-01), Zhang et al.
patent: 2003/0104499 (2003-06-01), Pressman et al.
patent: 2003/0165952 (2003-09-01), Linnarsson et al.
patent: 2003/0180791 (2003-09-01), Chinnadurai
patent: 2003/0198970 (2003-10-01), Roberts
patent: 2003/0198972 (2003-10-01), Erlander et al.
patent: 2003/0219771 (2003-11-01), Bevilacqua et al.
patent: 2003/0229455 (2003-12-01), Bevilacqua et al.
patent: 2004/0009489 (2004-01-01), Golub et al.
patent: 2004/0126775 (2004-07-01), Altieri et al.
patent: 2004/0133352 (2004-07-01), Bevilacqua et al.
patent: 2005/0048542 (2005-03-01), Baker et al.
patent: 0 108 564 (1988-05-01), None
patent: 1 365 034 (2003-11-01), None
patent: WO 99/02714 (1999-01-01), None
patent: WO 00/50595 (2000-08-01), None
patent: WO 00/55173 (2000-09-01), None
patent: WO 01/25250 (2001-04-01), None
patent: WO 01/40466 (2001-06-01), None
patent: WO 01/55320 (2001-08-01), None
patent: WO 01/70979 (2001-09-01), None
patent: WO 02/00677 (2002-01-01), None
patent: WO 02/06526 (2002-01-01), None
patent: WO 02/08260 (2002-01-01), None
patent: WO 02/08261 (2002-01-01), None
patent: WO 02/08282 (2002-01-01), None
patent: WO 02/08765 (2002-01-01), None
patent: WO 02/46467 (2002-06-01), None
patent: WO 02/017852 (2002-07-01), None
patent: WO 02/055988 (2002-07-01), None
patent: WO 02/059377 (2002-08-01), None
patent: WO 02/068579 (2002-09-01), None
patent: WO 02/103320 (2002-12-01), None
patent: WO 03/011897 (2003-02-01), None
patent: WO 03/078662 (2003-09-01), None
patent: WO 03/083096 (2003-10-01), None
patent: WO 2004/046386 (2004-06-01), None
van't Veer et al., Nature, 2002, vol. 415, pp. 530-536.
Cobleigh et al. Clinical Cancer Research, 2005, vol. 11, No. 24, pp. 8623.
Ayers, M. et al., “Gene Expression Profiles Predict Complete Pathologic Response to Neoadjuvant Paclitaxel and Fluorouracil, Doxorubicin, and Cyclophosphamide Chemotherapy in Breast Cancer,”Journal of Clinical Oncology, 22:(12), pp. 2284-2293, (2004).
Chang, J. et al., “Biologic Markers as Predictors of Clinical Outcome from Systemic Therapy for Primary Operable Breast Cancer,”Journal of Clinical Oncology, 17:(10), pp. 3058-3063, (1999).
Garber, K., “Gene Expression Tests Foretell Breast Cancer's Future,”Science, 303: pp. 1754-1755, (2004).
Paik, S. et al., “A Multigene Assay to Predict Recurrence of Tamoxifen-Treated, Node-Negative Breast Cancer,”The New England Journal of Medicine, 351:(27), pp. 2817-2826, (2004).
Ravdin, P.M. et al., “Computer Program to Assist in Making Decisions about Adjuvant Therapy for Women with Early Breast Cancer,”Journal of Clinical Oncology, 19:(4), pp. 980-991, (2001).
Brabender, Jan, et al.;Epidermal Growth Factor Receptor and HER2-neu mRNA Expression in Non-Small Cell Lung Cancer Is Correlated with Survival, Clinical Cancer Research; vol. 7, Jul. 2001; pp. 1850-1855.
Ding, Chunming, et al.;A high-throughput gene expression analysis technique using competitive PCR and matrix-assisted laser desorption ionization time-of-flight MS, PNAS, vol. 100:6; Mar. 18, 2003; pp. 3059-3064.
Cambridge Healthtech Institute Conference Agenda; “Enabling Molecular Profiling With Cellular Resolution: Microgenomics Using Homogeneous Cell Samples”; Dec. 2002; 5 pgs.
Yang, Li, et al.;BADGE,BeadsArray for theDetection ofGeneExpression, a High-Throughput Diagnostic Bioassay; Genome Research; vol. 11; 2001; pp. 1888-1898.
Abba et al., Gene expression signature of estrogen receptor a status in breast cancer. BMC Genomics 2005; 6:37.
Bertucci et al., Gene expression profiling of primary breast carcinomas using arrays of candidate genes. Human Molecular Genetics 2000;9(20):2981-91.
Chenard et al., High levels of stromelysin-3 correlate with poor prognosis in patients with breast carcinoma. Int. J. Cancer (Pred. Oncol.) 1996; 69:448-451.
Engel et al., Correlation between Stromelysin-3 mRNA level and outcome of human breast cancer. Int. J. Cancer. 1994; 58:830-5.
Fisher et al., Relative worth of estrogen or progesterone receptor and pathologic characteristics of differentiation as indicators of prognosis in node negative breast cancer patients: Findings from national surgical adjuvant breast and bowel project protocol B-06. J. Clin. Oncology 1988; 6(7):1076-87.
Gasparini et al., Expression of bcl-2 protein predicts efficacy of adjuvant treatments in operable node-positive breast cancer. Clinical Cancer Research 1995; 1(189-190):189-98.
Glinsky et al., Microarray analysis identifies a death-from=cancer signature predicting therapy failure in patients with multiple types of cancer. J. Clin. Investigation 2005; 115(6):1503-21.
Kononen et al., Tissue microarrays for high-throughput molecular profiling of tumor specimens. Nature Medicine 1998; 4(7):844-7.
Lah et al., Cathepsin B, a prognostic indicator in lymph node-negative breast carcinoma patients: Comparison with cathespin D, cathespin L, and other clinical indicators. Clinical Cancer Research 2000: 6:578-84.
Miyoshi et al., Association of centrosomal kinase STK15/BTAK mRNA expression with chromosomal instability in human breast cancers. Int. J. Cancer 2001; 92:370-3.
Modlich et al., Predictors of primary breast cancers responsiveness to preoperative Epirubicin/Cyclophosphamide-based chemotherapy: trans
Baker Joffre B.
Bryant John L.
Paik Soonmyung
Shak Steven
Borden Paula A.
Bozicevic Field & Francis LLP
Genomic Health, Inc.
Keddie James S.
NSABP Foundation, Inc.
LandOfFree
Predicting response to chemotherapy using gene expression... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Predicting response to chemotherapy using gene expression..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Predicting response to chemotherapy using gene expression... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2667648